Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

EAE vaccine supply issues set to continue
“As a responsible provider, we are actively addressing these issues to minimise the impact on customers” – Roy Geary.
Vaccine won’t be available until October at the earliest.

The Cevac Chlamydia vaccine for enzootic abortion of ewes (EAE) will not be available in September as anticipated, Ceva Animal Health has announced.

The delay to the delivery of the vaccine follows a gap in supply between June and August caused by a batch being out of specification. Ceva Animal Health submitted an Out of Specification request for the vaccine to be released, but the request was not successful.

The next batch may be available in October, but the manufacture has said there is no certainty that it will be.

Last year also saw supply issues with the vaccine, which were blamed on delays in the manufacturing and distribution process.

EAE is one of the most common infectious causes of abortion in ewes. It is estimated to cost the UK sheep industry up to £20 million a year.

Ceva Animal Health has said that it deeply regrets any inconvenience caused to sheep farmers.

Roy Geary, vice-president for Northern Europe (including the UK) at Ceva Animal Health, said: “The manufacturing of vaccines is a complex process that involves stringent quality control measures and adherence to regulatory guidelines.

“There have been unforeseen manufacturing issues at our production facilities, which have temporarily affected the ability to meet the demands of the UK sheep market within the main seasonal vaccination period for EAE.

“As a responsible provider, we are actively addressing these issues to minimise the impact on customers.”

Ceva Animal Health is recommending that veterinary surgeons and farmers follow advice issued by the Sheep Veterinary Society and Sheep Antibiotic Guardian Group which can accessed here.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.